BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21170093)

  • 1. BU- vs TBI-based conditioning for adult patients with ALL.
    Kalaycio M; Bolwell B; Rybicki L; Absi A; Andresen S; Pohlman B; Dean R; Sobecks R; Copelan E
    Bone Marrow Transplant; 2011 Nov; 46(11):1413-7. PubMed ID: 21170093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study.
    Bunin N; Aplenc R; Kamani N; Shaw K; Cnaan A; Simms S
    Bone Marrow Transplant; 2003 Sep; 32(6):543-8. PubMed ID: 12953124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation.
    Granados E; de La Cámara R; Madero L; Díaz MA; Martín-Regueira P; Steegmann JL; Arranz R; Figuera A; Fernández-Rañada JM
    Haematologica; 2000 Oct; 85(10):1060-7. PubMed ID: 11025598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
    Sisler IY; Koehler E; Koyama T; Domm JA; Ryan R; Levine JE; Pulsipher MA; Haut PR; Schultz KR; Taylor DS; Frangoul HA
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1620-7. PubMed ID: 19896086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
    Sakellari I; Gavriilaki E; Chatziioannou K; Papathanasiou M; Mallouri D; Batsis I; Bousiou Z; Bouziana S; Constantinou V; Douka V; Apostolou C; Iskas M; Lalayanni C; Athanasiadou A; Sotiropoulos D; Yannaki E; Gianouzakos V; Anagnostopoulos A
    Ann Hematol; 2018 Oct; 97(10):1987-1994. PubMed ID: 29869673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
    Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
    Abdelaty MM; Gawaly A; Fathy GM; Kabbash I; Taha A
    J Egypt Natl Canc Inst; 2020 Jun; 32(1):28. PubMed ID: 32537680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT.
    Cable C; Buzzeo MP; Schold JD; Khan S; Leather H; Moreb J; Jamieson K; Scornik J; Amdur RJ; Wingard JR; Reddy V
    Bone Marrow Transplant; 2010 Jan; 45(1):31-7. PubMed ID: 19543325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI.
    Garming-Legert K; Remberger M; Ringdén O; Hassan M; Dahllöf G
    Oral Dis; 2011 Oct; 17(7):670-6. PubMed ID: 21718391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.
    Kebriaei P; Anasetti C; Zhang MJ; Wang HL; Aldoss I; de Lima M; Khoury HJ; Sandmaier BM; Horowitz MM; Artz A; Bejanyan N; Ciurea S; Lazarus HM; Gale RP; Litzow M; Bredeson C; Seftel MD; Pulsipher MA; Boelens JJ; Alvarnas J; Champlin R; Forman S; Pullarkat V; Weisdorf D; Marks DI;
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):726-733. PubMed ID: 29197676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI.
    Bernard F; Bordigoni P; Simeoni MC; Barlogis V; Contet A; Loundou A; Thuret I; Leheup B; Chambost H; Play B; Auquier P; Michel G
    Bone Marrow Transplant; 2009 Apr; 43(8):637-42. PubMed ID: 19011662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of conditioning regimen on the outcome of bone marrow transplantation from an unrelated donor.
    Kanda Y; Sakamaki H; Sao H; Okamoto S; Kodera Y; Tanosaki R; Kasai M; Hiraoka A; Takahashi S; Miyawaki S; Kawase T; Morishima Y; Kato S;
    Biol Blood Marrow Transplant; 2005 Nov; 11(11):881-9. PubMed ID: 16275591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic transplantation for ALL in adults.
    Stein A; Forman SJ
    Bone Marrow Transplant; 2008 Mar; 41(5):439-46. PubMed ID: 18334992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia.
    Alexander BM; Wechsler D; Braun TM; Levine J; Herman J; Yanik G; Hutchinson R; Pierce LJ
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1191-6. PubMed ID: 15978741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.
    Takahata M; Hashino S; Okada K; Onozawa M; Kahata K; Sugita J; Shigematsu A; Kondo T; Yamamoto S; Endo T; Nishio M; Ito YM; Tanaka J; Koike T; Asaka M; Imamura M
    Am J Hematol; 2010 Apr; 85(4):243-8. PubMed ID: 20162540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
    Marks DI; Forman SJ; Blume KG; Pérez WS; Weisdorf DJ; Keating A; Gale RP; Cairo MS; Copelan EA; Horan JT; Lazarus HM; Litzow MR; McCarthy PL; Schultz KR; Smith DD; Trigg ME; Zhang MJ; Horowitz MM
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):438-53. PubMed ID: 16545728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.